Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$0.68 USD
-0.04 (-5.68%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $0.70 +0.02 (2.79%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CDTX 0.68 -0.04(-5.68%)
Will CDTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
GSK (GSK) Q3 Earnings and Revenues Surpass Estimates
Other News for CDTX
Buy Rating Affirmed for Cidara Therapeutics Amid Promising Oncology Program Developments
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
SLS, IBIO and ALDX are among premarket gainers
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio